9 news items
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
TAK
16 May 24
, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative
Scilex Holding Announce Final Court Approval Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit
SCLX
TAK
14 May 24
"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
in the field of active immunotherapy, we are developing an innovative approach that could change the treatment paradigm for Alzheimer's disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
.
"As pioneers in the field of active immunotherapy, we are developing an innovative approach that could change
r5g5cu7p60snqdqeiu1r1jbo6ngrcdpua2xr8xi7mms0hrmkze8rluw63 rz
TAK
9 May 24
approvals from the U.S. FDA in FY2023, Takeda's performance demonstrates the potential of our pipeline and our ability to bring our innovative medicines
76swkfzbc7vqx4fwoszzfd2tq2
TAK
22 Apr 24
Japan and toward the creation of innovative therapeutics
u2nl0u77kj1uws6idd95j4p6 diox0kg8ux4efgf1btb3m28xvlqsdugi
TAK
27 Mar 24
gastrointestinal diseases is unwavering. Alongside our continuous work on innovative treatments within our gastroenterology portfolio, we recognize the significant
tz1cxpvedi2a71k4ovx0vva2p5zk78qrowythaefaujgz ic07tlj
TAK
26 Mar 24
option specifically approved to treat this ultra-rare condition," said Yasushi Kajii, Head, R&D Japan Region at Takeda. "Developing innovative
- Prev
- 1
- Next